Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

BioVersys Reports Results From Phase 2a ENABLE Study

(RTTNews) - BioVersys AG (BIOV.SW) announced results from the Phase 2a ENABLE study of alpibectir in combination with ethionamide or AlpE in patients with newly diagnosed drug-sensitive pulmonary tuberculosis. The phase 2a ENABLE study showed early bactericidal activity in all re

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Finance & Markets

More from Friday 20 November →